**FIELD SAFETY NOTICE**

**ACTION REQUIRED**

**Erroneous results for Direct Bilirubin, Bilirubin Total (NBD), Creatinine (Jaffe), and Creatinine (Enzymatic) assay results due to interference by Eltrombopag and additional interference with Creatinine (Enzymatic) assay results by Phenindione**

September xx, 2020

CUSTOMER INFORMATION  
XXXXXX  
XXXXXX  
  
XXXXXXX

**Dear Valued Customer:**

The purpose of this letter is to advise you that Thermo Fisher Scientific Oy, part of Thermo Fisher Scientific Inc., is conducting a Field Safety Corrective Action (FSCA) for the in vitro diagnostic products as listed below (Table 1). Our records indicate that you have purchased units of the affected products.

REASON FOR FIELD CORRECTION

It has been identified that patients treated with Eltrombopag and/or Phenindione may receive incorrect test results as defined below. No incidents, injuries or incorrect patient results have been reported.

The information related to Phenindione and Eltrombopag interferences provided in this letter serves as supplemental instructions until the current Instructions For Use is updated.

**Table 1. PRODUCT INFORMATION**

|  |  |  |  |
| --- | --- | --- | --- |
| **Product Name** | **Product Code** | **Lot No.** | **Impact on test results** |
| **Bilirubin Direct** | 981909 981892 | All lots | Patients treated with **Eltrombopag**, may receive falsely low/high results |
| **Bilirubin Total (NBD)** | 981793 981897 | All lots | Patients treated with **Eltrombopag**, may receive falsely low/high results |
| **Creatinine (Jaffe)** | 981810 981811 | All lots | Patients treated with **Eltrombopag**, may receive falsely low/high results |
| **Creatinine (Enzymatic)** | 981845 981896 | All lots | Patients treated with **Eltrombopag**, may receive falsely low/high results |
| **Creatinine (Enzymatic)** | 981845  981896 | All lots | Patients treated with **Phenindione**, may receive falsely low results |

**Eltrombopag interference**

Eltrombopag in an oral thrombopoietin receptor agonist that may be used in the treatment of thrombocytopenia and/or aplastic anemia. It is highly coloured (reddish-brown) and reports show that it can cause serum/plasma discolouration. Interferences appears to be pH dependent and method specific. Eltrombopag is not frequently used as medication due to relatively narrow indication for use and its potential for significant side effects.

Patients treated with **Eltrombopag**, may receive falsely low/high results for the above listed products (see Table 1.).

**Phenindione interference**

Phenindione is an anticoagulant which functions as a Vitamin K antagonist. It has been identified that patients treated with Phenindione may receive falsely decreased creatinine results when using enzymatic creatinine method. Phenindione has serious potential side effects and is used infrequently.

Patients treated with **Phenindione**, may receive falsely low results for the above listed Creatinine (Enzymatic) products (see Table 1.).

**IMPACT ON PATIENT RESULTS:**

The risk of misdiagnosis and inappropriate therapy exist, especially if results are assessed separately. For diagnostic purposes, the result should always be assessed with the patient’s medical history, clinical examination and other diagnostic findings.

According to the information at hand, the two medications, Eltrombopag and Phenindione, are infrequently prescribed due to the potential for significant side effects.

**ACTIONS TO BE TAKEN BY THE CUSTOMER / USER:**

1. If laboratory results of above mentioned tests are inconsistent with clinical observations for patients treated with Eltrombopag, measurements should be repeated using another method. Special attention on choosing the appropriate method for assessing potential drug induced hepatotoxicity is needed as Eltrombopag interferes with Bilirubin assays.
2. Results obtained from patients under Phenindione therapy with Creatinine (enzymatic) assay, should not be used for diagnosis. Measurements should be repeated using another method, e.g. Creatinine Jaffe.
3. Retain a copy of this letter for your laboratory records.
4. As appropriate, contact your Medical Professional for evaluation of further action.
5. Please, fill out the MEDICAL DEVICE FIELD CORRECTION -Response Form and return it within 5 days of the date of this letter to your distributor as instructed in the form and as listed below:

FAX: [add distributor contact information] or

Email: [add distributor contact information]

**TYPE OF ACTIONS TO BE TAKEN BY THE MANUFACTURER:**

Thermo Fisher Scientific Oy has informed the appropriate Regulatory Agencies in the European Union of this field safety corrective action.

We appreciate your immediate attention to this Field Safety Corrective Action. We apologize for any inconvenience this may have caused and appreciate your understanding as we take action to ensure customer safety and satisfaction.

If you have any further questions, please contact your local Thermo Fisher Scientific representative by sending an email to [add distributor contact information].

Sincerely,

Rina Wahlroos

Director, Quality Systems and Compliance Affairs

Thermo Fisher Scientific Oy

Analyzers & Automation

Clinical Diagnostics

**MEDICAL DEVICE FIELD CORRECTION**

**Response Form**

**Erroneous results for Direct Bilirubin, Bilirubin Total (NBD), Creatinine (Jaffe), and Creatinine (Enzymatic) assay results due to interference by Eltrombopag and additional interference with Creatinine (Enzymatic) assay results by Phenindione**

I have read and understand the attached Field Safety Notice and field action instructions: \_\_\_\_\_ (initials)

I understand that this applies to all inventory of the affected in vitro diagnostic medical device products listed in Table 1 that I have received: \_\_\_\_\_\_ (initials)

Do you have any knowledge of adverse medical events associated with the products listed in this Field Safety Notice?

\_\_\_\_\_ Yes \_\_\_\_\_ No

If yes, please explain:

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**RETURN RESPONSE (please provide additional information, if applicable):**

|  |
| --- |
|  |

**PLEASE RETURN COMPLETED AND SIGNED FORM TO EMAIL:** [add distributor contact information]

**Signature of Acknowledgement and Receipt by Customer:**

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

|  |  |
| --- | --- |
| **Customer Name/Title:** |  |
| **Date:** |  |
| **Company/Institute:** |  |
| **Telephone:** |  |
| **Email Address:** |  |

**It is important that your organisation takes action as detailed in this letter and also replies without delay by using this response form. Your reply is evidence, which Thermo Fisher Scientific and Regulatory Agencies need to monitor the progress of FSCAs. Without your reply Thermo Fisher Scientific Oy cannot verify the effectiveness or completeness of this Field Safety Corrective Action.**